Literature DB >> 21030704

Influence of prophylactic, endovascularly based normothermia on inflammation in patients with severe cerebrovascular disease: a prospective, randomized trial.

Gregor Broessner1, Peter Lackner, Marlene Fischer, Ronny Beer, Raimund Helbok, Bettina Pfausler, Dietmar Schneider, Erich Schmutzhard.   

Abstract

BACKGROUND AND
PURPOSE: We analyzed the impact of long-term endovascularly based prophylactic normothermia versus conventional temperature management on inflammatory parameters in patients with severe cerebrovascular disease.
METHODS: This was a prospective, randomized, controlled trial comparing the course of inflammatory parameters between the 2 treatment arms: (1) prophylactically endovascular long-term normothermia; and (2) conventional, stepwise fever management with antiinflammatory drugs and surface cooling. Inclusion criteria were (1) spontaneous subarachnoid hemorrhage with Hunt-Hess grade between 3 and 5; (2) spontaneous intracerebral hemorrhage with a Glasgow Coma Scale score of ≤ 10; or (3) complicated cerebral infarction requiring intensive care unit treatment with a NIH Stroke Scale score of ≥ 15. Treatment period was 336 hours in subarachnoid hemorrhage patients and 168 hours in patients with complicated stroke or intracerebral hemorrhage patients.
RESULTS: A total of 102 patients (56 female) were enrolled during a 3.5-year period. Overall median total fever burden during the course of treatment was 0.0°C hour and 4.3°C hours in the catheter and conventional group, respectively (P < 0.0001). C-reactive protein and interleukin-6 were significantly elevated in the endovascular group (P < 0.05). Nonsteroidal antiinflammatory drugs, used as additional treatment of fever, significantly reduced mean C-reactive protein in endovascular treated patients (P < 0.01).
CONCLUSIONS: The proinflammatory cytokines C-reactive protein and interleukin-6 were significantly elevated in patients receiving prophylactic endovascularly based long-term normothermia. Nonsteroidal antiinflammatory drugs significantly affected the course of proinflammatory parameters; thus, future trials should investigate the role of nonsteroidal antiinflammatory drugs in severe cerebrovascular disease patients and their interaction with temperature management. Clinical Trial Registration-Trial not registered; enrollment began before July 2005.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030704     DOI: 10.1161/STROKEAHA.110.591933

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Fever control in the NICU: is there still a simpler and cheaper solution?

Authors:  Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2011-12       Impact factor: 3.210

2.  Temperature Management in the Neurointensive Care Unit.

Authors:  George A Lopez
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

3.  Safety, Feasibility, and Efficiency of a New Cooling Device Using Intravenous Cold Infusions for Fever Control.

Authors:  J F Willms; O Boss; E Keller
Journal:  Neurocrit Care       Date:  2019-02       Impact factor: 3.210

Review 4.  Autonomic dysfunction syndromes after acute brain injury.

Authors:  Courtney Takahashi; Holly E Hinson; Ian J Baguley
Journal:  Handb Clin Neurol       Date:  2015

5.  Risk of thromboembolic events with endovascular cooling catheters in patients with subarachnoid hemorrhage.

Authors:  Achim Müller; Andreas Lorenz; Burkhardt Seifert; Emanuela Keller
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

6.  The impact of nonsteroidal anti-inflammatory drugs on inflammatory response after aneurysmal subarachnoid hemorrhage.

Authors:  Carl Muroi; Michael Hugelshofer; Martin Seule; Emanuela Keller
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

7.  Early brain injury after aneurysmal subarachnoid hemorrhage: a multimodal neuromonitoring study.

Authors:  Raimund Helbok; Alois Josef Schiefecker; Ronny Beer; Anelia Dietmann; Ana Patrícia Antunes; Florian Sohm; Marlene Fischer; Werner Oskar Hackl; Paul Rhomberg; Peter Lackner; Bettina Pfausler; Claudius Thomé; Christian Humpel; Erich Schmutzhard
Journal:  Crit Care       Date:  2015-03-09       Impact factor: 9.097

Review 8.  Should we treat pyrexia? And how do we do it?

Authors:  James F Doyle; Frédérique Schortgen
Journal:  Crit Care       Date:  2016-10-03       Impact factor: 9.097

Review 9.  Role of Interleukin-10 in Acute Brain Injuries.

Authors:  Joshua M Garcia; Stephanie A Stillings; Jenna L Leclerc; Harrison Phillips; Nancy J Edwards; Steven A Robicsek; Brian L Hoh; Spiros Blackburn; Sylvain Doré
Journal:  Front Neurol       Date:  2017-06-12       Impact factor: 4.003

10.  Hyperpyrexia in life-threatening central nervous system infection - It is the timepoint of fever which matters: A plea to select the best timing and optimal methods of temperature management.

Authors:  Schmutzhard Erich; Pfausler Bettina
Journal:  Brain Circ       Date:  2017-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.